Heparin Dosing and Frequency
For therapeutic anticoagulation in venous thromboembolism (VTE), use weight-based IV heparin: 80 units/kg bolus followed by 18 units/kg/hour continuous infusion, targeting an aPTT of 1.5-2.5 times control or anti-Xa level of 0.30-0.70 U/mL 1, 2.
Therapeutic Anticoagulation Regimens
Intravenous Administration (Preferred)
Weight-based dosing is superior to fixed dosing and reduces recurrent thromboembolism 1. The evidence clearly demonstrates that patients receiving weight-adjusted heparin achieve therapeutic levels faster and have significantly lower VTE recurrence rates.
Initial dosing options:
- 80 units/kg IV bolus, then 18 units/kg/hour continuous infusion (preferred, evidence-based) 1
- Alternative: 5,000 units IV bolus, then at least 32,000 units/24 hours (minimum 1,333 units/hour) 3, 2
Target monitoring parameters:
- aPTT ratio: 1.5-2.5 times control 3
- Anti-Xa level: 0.30-0.70 U/mL 3, 4
- Anti-Xa assays are preferred over aPTT as they have fewer interferences 4
Subcutaneous Administration
For therapeutic SC dosing:
- 5,000 units IV bolus, then 250 units/kg SC every 12 hours 1
- Alternative: 333 units/kg SC initial dose, then 250 units/kg SC every 12 hours 1
Important caveat: SC administration has reduced bioavailability compared to IV, which historically led to higher recurrence rates when inadequate doses were used 1.
Prophylactic Anticoagulation
For VTE prophylaxis in medical/surgical patients: 5,000 units SC every 8-12 hours 2.
Frequency Considerations
The evidence on BID vs TID dosing shows:
- TID (every 8 hours) provides slightly better VTE prevention (3.1% VTE rate vs 4.0% with BID) but increases bleeding risk (4.3% vs 3.2%) 5, 6
- BID (every 12 hours) is more appropriate for general medical populations given the bleeding risk-benefit profile 5, 6
- Use TID dosing for higher-risk patients where VTE prevention outweighs bleeding concerns 6
Acute Coronary Syndromes
Lower doses are used to reduce bleeding when combined with antiplatelet agents:
- 60-70 units/kg bolus (maximum 5,000 units) 1, 7
- 12-15 units/kg/hour infusion 7
- Target aPTT: 50-70 seconds 7
Monitoring and Dose Adjustment
Timing of laboratory monitoring:
- For IV infusion: Check aPTT/anti-Xa 6 hours after initiation or dose change 3
- For SC dosing: Check 4-6 hours after injection 2
- Achieving therapeutic levels within 24 hours reduces mortality 1
Sample handling: Centrifuge within 1 hour of collection, test within 10 minutes (1 hour acceptable) 4
Special Populations
Pediatric dosing:
- Initial: 50 units/kg IV bolus 2
- Maintenance: 100 units/kg IV every 4 hours, or 20,000 units/m²/24 hours continuous infusion 2
Geriatric patients (>60 years): May require lower doses 2
Critical Pitfalls to Avoid
- Underdosing in the first 24 hours is the most common error and directly increases VTE recurrence and mortality 1
- Using fixed-dose regimens instead of weight-based dosing for therapeutic anticoagulation leads to subtherapeutic levels 1
- Delaying achievement of therapeutic aPTT beyond 24 hours increases adverse outcomes 1
- Not accounting for reduced SC bioavailability when switching from IV to SC routes
Duration and Transition
When transitioning to oral anticoagulation, continue full-dose heparin for several days after achieving therapeutic INR, then discontinue without tapering 2.
Note: Current evidence favors low-molecular-weight heparin (LMWH) over unfractionated heparin for most VTE cases due to superior efficacy, lower bleeding rates, and ease of use 8. UFH remains indicated when rapid reversibility is needed (e.g., high bleeding risk, renal failure, or planned procedures).